Clinical Trial Search

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Patients Who Survive Progression-free for at Least 6 Months — 6; 14 Participants

Primary: Overview of Treatment-emergent Adverse Events (TEAEs) — 3; 13; 11; 2 Participants

Primary: Pathologic Complete Response Rates — 8 participants

Primary: Efficacy: Progression-free Survival (PFS) — 4.3; 2.8; 5.3; 2.8 Months — p=0.0220

Primary: PFS — 29.8 Months

Primary: Progression-free Survival at 6 Months — 40.3 percentage of participants

Primary: Percentage of Patients in Remission at 1 Year — 38.1; 38.8 percentage of participants

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Proportion of Patients With Complete and Partial Tumor Response — 0.26 Proportion of patients

Primary: Four Cycle Progression-free Survival Rate — 8 Participants

Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Safety of the Vaccine — 0; 9 participants

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed…

Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341

Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…

Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants

Primary: Progression-free Survival (PFS) > 6 Months — 8.0 percentage of participants

Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months

Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants

Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR) — 2.5; 0; 15; 40 Percentage of Participants

Primary: Progression-free Survival — 8.85; 8.32 months

Primary: Tumor Response Duration — 3.9; 24.1 months

Primary: Twelve-month Progression-free Survival (PFS) Rate in Participants — 65.7 percentage of participants

Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 Participants

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2